A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Core Laboratories Inc. /DE/
CLB
$550M
Mkt Cap
$11.67
-1.10%
Core Laboratories Inc. /DE/ (CLB) has a current P/E ratio of 17.2, compared to its historical median P/E of 25.3. The stock is currently considered Fair based on its historical valuation range.
Core Laboratories Inc. /DE/ (CLB) has a 5-year average return on invested capital (ROIC) of 10.6%. This indicates solid capital allocation.
Core Laboratories Inc. /DE/ (CLB) has a market capitalization of $537M. It is classified as a small-cap stock.
Yes, Core Laboratories Inc. /DE/ (CLB) pays a dividend with a trailing twelve-month yield of 0.35%. The company also returns capital through share buybacks, with a buyback yield of 2.68%.
Based on historical P/E analysis, Core Laboratories Inc. /DE/ (CLB) appears fair. The current P/E of 17.2 is 32% below its historical median of 25.3. The estimated fair value CAGR (P/E method) is 9.0%.
Core Laboratories Inc. /DE/ (CLB) operates in the Oil & Gas Field Services, Nec industry, within the Energy sector.
Core Laboratories Inc. /DE/ (CLB) reported annual revenue of $527 million in its most recent fiscal year, based on SEC EDGAR filings.
Core Laboratories Inc. is a Delaware corporation. We were established in 1936 and are one of the world’s leading providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, primarily through client relationships with many of the world’s major, national and independent oil companies. These services and products can enable our clients to evaluate and improve reservoir performance and increase oil and gas recovery from their new and existing fields. We make measurements on reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. In addition, we assist clients in evaluating subsurface targets associated with Carbon Capture and Sequestration (“CCS”) projects or initiatives. We have over 70 offices in more than 50 countries and have approximately 3,500 employees. On May 1, 2023, Core Laboratories N.V.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 525M | 527M | 524M | 510M | 490M | 470M |
| Net Income | 29M | 30M | 31M | 37M | 19M | 20M |
| EPS | $0.63 | $0.63 | $0.66 | $0.77 | $0.42 | $0.42 |
| Free Cash Flow | 22M | 26M | 45M | 14M | 15M | 23M |
| ROIC | 8.3% | 7.9% | 9.0% | 12.5% | 8.5% | 15.1% |
| Gross Margin | - | 20.7% | 19.7% | 21.5% | 19.6% | - |
| Debt/Equity | 0.74 | 0.93 | 0.94 | 1.03 | 0.94 | 0.96 |
| Dividends/Share | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 | $0.04 |
| Operating Income | 54M | 56M | 59M | 55M | 42M | 45M |
| Operating Margin | 10.3% | 10.7% | 11.2% | 10.7% | 8.5% | 9.6% |
| ROE | 10.8% | 11.6% | 13.3% | 17.9% | 11.3% | 16.7% |
| Shares Outstanding | 46M | 47M | 48M | 48M | 46M | 47M |
| Metric | ||||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 470M | 490M | 510M | 524M | 527M | 525M |
| Gross Margin | N/A | 19.6% | 21.5% | 19.7% | 20.7% | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | 38M | 40M | 40M | 45M | 47M |
| EBIT | 45M | 42M | 55M | 59M | 56M | 54M |
| Op. Margin | 9.6% | 8.5% | 10.7% | 11.2% | 10.7% | 10.3% |
| Net Income | 20M | 19M | 37M | 31M | 30M | 29M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% | 5.5% |
| Non-Recurring | 427K | 46M | 42M | 40M | 34M | 30M |
| Returns on Capital | ||||||
| ROIC | 15.1% | 8.5% | 12.5% | 9.0% | 7.9% | 8.3% |
| ROE | 16.7% | 11.3% | 17.9% | 13.3% | 11.6% | 10.8% |
| ROA | 3.4% | 3.4% | 6.3% | 5.4% | 5.1% | 4.9% |
| Cash Flow | ||||||
| Op. Cash Flow | 37M | 25M | 25M | 56M | 37M | 34M |
| Free Cash Flow | 23M | 15M | 14M | 45M | 26M | 22M |
| Owner Earnings | -1.0M | 39K | -5.0M | 38M | 15M | 12M |
| CapEx | 14M | 10M | 11M | 12M | 11M | 12M |
| Maint. CapEx | 19M | 17M | 16M | 15M | 15M | 15M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 19M | 17M | 16M | 15M | 15M | 15M |
| CapEx/OCF | N/A | 40.9% | 42.7% | 23.1% | N/A | 34.6% |
| Capital Allocation | ||||||
| Dividends Paid | 1.8M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M |
| Dividend Yield | N/A | 0.2% | 0.2% | 0.2% | N/A | 0.3% |
| Share Buybacks | 8.3M | 3.9M | 2.2M | 5.3M | 12M | 14M |
| Buyback Yield | 0.0% | 0.5% | 0.3% | 0.7% | 0.0% | 2.7% |
| Stock-Based Comp | 19M | 7.8M | 14M | 3.8M | 7.1M | 8.0M |
| Debt Repayment | 226M | 131M | 211M | 82M | 63M | 63M |
| Balance Sheet | ||||||
| Net Debt | 137M | 157M | 217M | 213M | 224M | 177M |
| Cash & Equiv. | 18M | 15M | 15M | 19M | 23M | 23M |
| Long-Term Debt | 155M | 172M | 163M | 126M | 110M | 114M |
| Debt/Equity | 0.96 | 0.94 | 1.03 | 0.94 | 0.93 | 0.74 |
| Interest Coverage | 4.9 | 3.6 | 4.1 | 4.7 | 5.3 | 5.0 |
| Equity | 161M | 184M | 225M | 247M | 266M | 269M |
| Total Assets | 581M | 578M | 586M | 585M | 584M | 588M |
| Total Liabilities | 420M | 389M | 357M | 333M | 312M | -845K |
| Intangibles | N/A | 7.5M | 6.9M | 6.4M | 7.1M | 6.9M |
| Retained Earnings | N/A | 86M | 121M | 145M | 173M | 171M |
| Working Capital | N/A | 109M | 135M | 119M | 109M | 110M |
| Current Assets | N/A | 212M | 223M | 221M | 215M | 214M |
| Current Liabilities | N/A | 103M | 88M | 102M | 106M | 105M |
| Per Share Data | ||||||
| EPS | 0.42 | 0.42 | 0.77 | 0.66 | 0.63 | 0.63 |
| Owner EPS | -0.02 | 0.00 | -0.10 | 0.79 | 0.32 | 0.25 |
| Book Value | 3.43 | 3.98 | 4.72 | 5.18 | 5.65 | 5.84 |
| Cash Flow/Share | 0.78 | 0.54 | 0.52 | 1.19 | 0.79 | 0.95 |
| Dividends/Share | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Shares Out. | 47.0M | 46.3M | 47.6M | 47.6M | 47.1M | 46.0M |
| Valuation | ||||||
| P/E Ratio | N/A | 44.3 | 23.4 | 25.3 | N/A | 18.6 |
| P/FCF | N/A | 58.4 | 60.3 | 17.8 | N/A | 23.9 |
| EV/EBIT | N/A | 24.2 | 18.1 | 15.1 | N/A | 13.2 |
| Price/Book | N/A | 4.7 | 3.8 | 3.1 | N/A | 2.0 |
| Price/Sales | N/A | 2.1 | 2.1 | 1.6 | N/A | 1.0 |
| FCF Yield | N/A | 1.7% | 1.7% | 5.6% | N/A | 4.2% |
| Market Cap | 0 | 861M | 857M | 794M | 0 | 537M |
| Avg. Price | 0.00 | 22.47 | 22.51 | 18.15 | 0.00 | 11.67 |
| Year-End Price | 0.00 | 18.60 | 17.98 | 16.68 | 0.00 | 11.67 |
Core Laboratories Inc. /DE/ passes 4 of 9 quality checks, suggesting mixed fundamentals.
Core Laboratories Inc. /DE/ trades at 17.2x trailing earnings, compared to its 15-year median P/E of 25.3x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 14.7x vs a median of 58.4x. The company's 5-year average ROIC is 10.6% with a gross margin of 20.4%. Total shareholder yield (dividends + buybacks) is 3.0%. At current prices, the estimated annualized return to fair value is +13.1%.
Core Laboratories Inc. /DE/ (CLB) has a net profit margin of 5.6%. This is a modest margin.
Core Laboratories Inc. /DE/ (CLB) generated $26 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Core Laboratories Inc. /DE/ (CLB) has a debt-to-equity ratio of 0.93. This indicates moderate leverage.
Core Laboratories Inc. /DE/ (CLB) reported earnings per share (EPS) of $0.63 in its most recent fiscal year.
Core Laboratories Inc. /DE/ (CLB) has a return on equity (ROE) of 11.6%. This indicates moderate shareholder returns.
Core Laboratories Inc. /DE/ (CLB) has a 5-year average gross margin of 20.4%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 5 years of financial data for Core Laboratories Inc. /DE/ (CLB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Core Laboratories Inc. /DE/ (CLB) has a book value per share of $5.65, based on its most recent annual SEC filing.
No recent press releases.